SCM
ALDX icon

Segantii Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Segantii Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-200,000
Closed -$2.27M – 506
2021
Q2 		$2.27M Buy
+200,000
New +$2.4M 0.07% 148

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Segantii Capital Management's ALDX Position: Q3 2021 in Review

Segantii Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2021, closing a stake of 200,000 shares — an estimated $2.27M sold.

Segantii Capital Management first reported a position in ALDX in Q2 2021 and held it in 1 quarter. The position peaked at $2.27M in Q2 2021. 117 funds tracked by Wall St. Rank hold ALDX as of Q3 2021.

  • Segantii Capital Management reported no remaining Aldeyra Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Segantii Capital Management sold 200,000 Aldeyra Therapeutics shares in Q3 2021, an estimated $2.27M.
  • Segantii Capital Management first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 1 quarter.
  • Segantii Capital Management's Aldeyra Therapeutics position peaked at $2.27M in Q2 2021.
  • 117 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2021.

Based on Segantii Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.